Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19
Hyundai Bioscience announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing ‘Poly-COV01,’ an injection drug for the potential treatment of patients…